Effects of Tadalafil on Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia in Men With or Without Erectile Dysfunction

Urology

Volumn 75, Issue 6, 2010, Pages 1452-1457

  Broderick, Gregory A ^a   Brock, Gerald B ^b   Roehrborn, Claus G ^c   Watts, Steven D ^d   Elion Mboussa, Albert ^d   Viktrup, Lars ^d  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TADALAFIL;

ADULT; AGE DISTRIBUTION; ARTICLE; BACKACHE; BENIGN PROSTATIC HYPERPLASIA IMPACT INDEX; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ERECTILE DYSFUNCTION; GASTROESOPHAGEAL REFLUX; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INTERNATIONAL PROSTATE SYMPTOM SCORE; LIMB PAIN; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; POST HOC ANALYSIS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCORING SYSTEM; SINGLE BLIND PROCEDURE; TREATMENT DURATION;

AGED; CARBOLINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ERECTILE DYSFUNCTION; FOLLOW-UP STUDIES; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PROBABILITY; PROSTATIC HYPERPLASIA; PROSTATISM; QUALITY OF LIFE; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; URINATION DISORDERS; URODYNAMICS;

EID: 77952742883     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.09.093     Document Type: Article

References (30)

1. Jacobsen S.J., Girman C.J., Guess H.A., et al. Natural history of prostatism: factors associated with discordance between frequency and bother of urinary symptoms. Urology 42 (1993) 663-671
2. Girman C.J., Epstein R.S., Jacobsen S.J., et al. Natural history of prostatism: impact of urinary symptoms on quality of life in 2115 randomly selected community men. Urology 44 (1994) 825-831
3. Rosen R.C., and Kostis J.B. Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am J Cardiol 92 (2003) 9-18
4. Johannes C.B., Araujo A.B., Feldman H.A., et al. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol 163 (2000) 460-463
5. Rosen R., Altwein J., Boyle P., et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 44 (2003) 637-649
6. Braun M.H., Sommer F., Haupt G., et al. Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical "Aging Male" symptoms?. Results of the "Cologne Male Survey.". Eur Urol 44 (2003) 588-594
7. Kohler T.S., and McVary K.T. The relationship between erectile dysfunction and lower urinary tract symptoms and the role of phosphodiesterase type 5 inhibitors. Eur Urol 55 (2008) 38-48
8. Shiri R., Hakkinen J.T., Hakama M., et al. Effect of lower urinary tract symptoms on the incidence of erectile dysfunction. J Urol 174 (2005) 205-209
9. Rosen R.C., Wei J.T., Althof S.E., et al. Association of sexual dysfunction with lower urinary tract symptoms of BPH and BPH medical therapies: results from the BPH Registry. Urology 73 (2009) 562-566
10. Bing W., Chang S., Hypolite J.A., et al. Obstruction-induced changes in urinary bladder smooth muscle contractility: a role for Rho kinase. Am J Physiol Renal Physiol 285 (2003) F990-F997
11. Chitaley K., Wingard C.J., Clinton W.R., et al. Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway. Nat Med 7 (2001) 119-122
12. Khan M.A., Thompson C.S., Dashwood M.R., et al. Endothelin-1 and nitric oxide in the pathogenesis of urinary tract disorders secondary to bladder outlet obstruction. Curr Vasc Pharmacol 1 (2003) 27-31
13. Tarcan T., Azadzoi K.M., Siroky M.B., et al. Age-related erectile and voiding dysfunction: the role of arterial insufficiency. Br J Urol 82 suppl 1 (1998) 26-33
14. Lepor H., Gup D.I., Baumann M., et al. Comparison of alpha 1 adrenoceptors in the prostate capsule of men with symptomatic and asymptomatic benign prostatic hyperplasia. Br J Urol 67 (1991) 493-498
15. McVary K.T., Rademaker A., Lloyd G.L., et al. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 174 (2005) 1327-1333
16. American Urological Association (AUA) Benign Prostatic Hyperplasia (BPH) Guideline Update Panel. Guideline on the management of benign prostatic hyperplasia (BPH) (2006). http://www.auanet.org/guidelines/bph.cfm
17. McVary K.T., Monnig W., Camps Jr. J.L., et al. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 177 (2007) 1071-1077
18. Stief C.G., Porst H., Neuser D., et al. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 53 (2008) 1236-1244
19. Roehrborn C.G., McVary K.T., Elion-Mboussa A., et al. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 180 (2008) 1228-1234
20. Porst H., McVary K.T., Montorsi F., et al. Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. Eur Urol 56 (2009) 727-736
21. Bittencourt J.A., Tano T., Gajar S.A., et al. Relaxant effects of sildenafil on the human isolated bladder neck. Urology 73 (2009) 427-430
22. Uckert S., Sormes M., Kedia G., et al. Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue. Urology 71 (2008) 526-530
23. Palea S., Rekik M., Rischmann P., et al. Tadalafil exerts an additive effect on alfuzosin-induced relaxation in pre-contracted human isolated prostatic adenoma. Urology 7 (2008) 170
24. Beamon C.R., Mazar C., Salkini M.W., et al. The effect of sildenafil citrate on bladder outlet obstruction: a mouse model. BJU Int 104 (2009) 252-256
25. Gacci M., Del P.G., Macchiarella A., et al. Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study. J Urol 178 (2007) 2040-2043
26. Morelli A., Filippi S., Sandner P., et al. Vardenafil modulates bladder contractility through cGMP-mediated inhibition of RhoA/Rho kinase signaling pathway in spontaneously hypertensive rats. J Sex Med 6 (2009) 1594-1608
27. Azadzoi K.M., Babayan R.K., Kozlowski R., et al. Chronic ischemia increases prostatic smooth muscle contraction in the rabbit. J Urol 170 (2003) 659-663
28. Berger A.P., Deibl M., Leonhartsberger N., et al. Vascular damage as a risk factor for benign prostatic hyperplasia and erectile dysfunction. BJU Int 96 (2005) 1073-1078
29. Ehren I., Iversen H., Jansson O., et al. Localization of nitric oxide synthase activity in the human lower urinary tract and its correlation with neuroeffector responses. Urology 44 (1994) 683-687
30. Lagakos S.W. The challenge of subgroup analyses-reporting without distorting. N Engl J Med 354 (2006) 1667-1669